US6433154B1
(en)
|
1997-06-12 |
2002-08-13 |
Bristol-Myers Squibb Company |
Functional receptor/kinase chimera in yeast cells
|
US20030206958A1
(en)
*
|
2000-12-22 |
2003-11-06 |
Cattaneo Maurizio V. |
Chitosan biopolymer for the topical delivery of active agents
|
AU4724401A
(en)
*
|
2000-02-28 |
2001-09-12 |
Genesegues Inc |
Nanocapsule encapsulation system and method
|
WO2001087491A1
(en)
|
2000-05-16 |
2001-11-22 |
Regents Of The University Of Minnesota |
High mass throughput particle generation using multiple nozzle spraying
|
US8067032B2
(en)
|
2000-12-22 |
2011-11-29 |
Baxter International Inc. |
Method for preparing submicron particles of antineoplastic agents
|
US20050048126A1
(en)
|
2000-12-22 |
2005-03-03 |
Barrett Rabinow |
Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
|
US9700866B2
(en)
|
2000-12-22 |
2017-07-11 |
Baxter International Inc. |
Surfactant systems for delivery of organic compounds
|
US20030096013A1
(en)
*
|
2000-12-22 |
2003-05-22 |
Jane Werling |
Preparation of submicron sized particles with polymorph control
|
US7247338B2
(en)
*
|
2001-05-16 |
2007-07-24 |
Regents Of The University Of Minnesota |
Coating medical devices
|
MXPA03011935A
(en)
*
|
2001-06-22 |
2004-03-26 |
Pfizer Prod Inc |
Pharmaceutical compositions containing polymer and drug assemblies.
|
US7081489B2
(en)
*
|
2001-08-09 |
2006-07-25 |
Florida State University Research Foundation |
Polymeric encapsulation of nanoparticles
|
MXPA04002446A
(en)
|
2001-09-26 |
2004-07-23 |
Baxter Int |
Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal.
|
US20060003012A9
(en)
|
2001-09-26 |
2006-01-05 |
Sean Brynjelsen |
Preparation of submicron solid particle suspensions by sonication of multiphase systems
|
US7491810B2
(en)
*
|
2001-11-30 |
2009-02-17 |
U.S. Department Of Veterans Affairs |
Transgenic screen and method for screening modulators of brain-derived neurotrophic factor (BDNF) production
|
US7615676B2
(en)
*
|
2001-11-30 |
2009-11-10 |
U.S. Department Of Veterans Affairs |
Transgenic screen and method for screening modulators of brain-derived neurotrophic factor (BDNF) production
|
US20040038303A1
(en)
*
|
2002-04-08 |
2004-02-26 |
Unger Gretchen M. |
Biologic modulations with nanoparticles
|
US7053034B2
(en)
*
|
2002-04-10 |
2006-05-30 |
Salvona, Llc |
Targeted controlled delivery compositions activated by changes in pH or salt concentration
|
DE10236064A1
(en)
*
|
2002-08-07 |
2004-02-19 |
Beiersdorf Ag |
Foaming sunscreen preparations
|
US6989196B2
(en)
*
|
2002-10-02 |
2006-01-24 |
Florida State University Research Foundation |
Microencapsulation of magnetic material using heat stabilization
|
US20060018882A1
(en)
*
|
2004-06-21 |
2006-01-26 |
Kaemmerer William F |
Medical devices and methods for delivering compositions to cells
|
US7618948B2
(en)
*
|
2002-11-26 |
2009-11-17 |
Medtronic, Inc. |
Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
|
US7605249B2
(en)
|
2002-11-26 |
2009-10-20 |
Medtronic, Inc. |
Treatment of neurodegenerative disease through intracranial delivery of siRNA
|
US7829694B2
(en)
|
2002-11-26 |
2010-11-09 |
Medtronic, Inc. |
Treatment of neurodegenerative disease through intracranial delivery of siRNA
|
US7994149B2
(en)
|
2003-02-03 |
2011-08-09 |
Medtronic, Inc. |
Method for treatment of Huntington's disease through intracranial delivery of sirna
|
US7732591B2
(en)
*
|
2003-11-25 |
2010-06-08 |
Medtronic, Inc. |
Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna
|
US9044381B2
(en)
*
|
2003-06-24 |
2015-06-02 |
Baxter International Inc. |
Method for delivering drugs to the brain
|
US8986736B2
(en)
*
|
2003-06-24 |
2015-03-24 |
Baxter International Inc. |
Method for delivering particulate drugs to tissues
|
BRPI0412734A
(en)
*
|
2003-07-17 |
2006-09-26 |
Tibotec Pharm Ltd |
process for preparing particles containing an antiviral
|
EP1680073B1
(en)
*
|
2003-10-21 |
2013-01-02 |
IGF Oncology, LLC |
Compounds and method for treating cancer
|
US9011880B2
(en)
*
|
2003-10-21 |
2015-04-21 |
Igf Oncology, Llc |
Compounds and methods for treating cancer
|
WO2005072292A2
(en)
*
|
2004-01-24 |
2005-08-11 |
Hugh Mctavish |
Methods for enhancing radiation therapy
|
US20050202094A1
(en)
*
|
2004-01-29 |
2005-09-15 |
Werling Jane O. |
Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
|
KR20050081092A
(en)
*
|
2004-02-12 |
2005-08-18 |
한국과학기술연구원 |
Composition and formulation of colloidal system comprising biocompatible aqueous-soluble polymer, and preparation method thereof
|
US7354980B1
(en)
|
2004-03-12 |
2008-04-08 |
Key Medical Technologies, Inc. |
High refractive index polymers for ophthalmic applications
|
US20050208090A1
(en)
*
|
2004-03-18 |
2005-09-22 |
Medtronic, Inc. |
Methods and systems for treatment of neurological diseases of the central nervous system
|
CA2565236A1
(en)
*
|
2004-05-06 |
2005-11-17 |
Ivrea Pharmaceuticals, Inc. |
Particles for the delivery of active agents
|
US7842281B2
(en)
*
|
2004-05-10 |
2010-11-30 |
The Florida State University Research Foundation |
Magnetic particle composition for therapeutic hyperthermia
|
BRPI0510271A
(en)
*
|
2004-06-15 |
2007-10-30 |
Baxter Int |
Ex vivo applications microparticulate therapeutic agents
|
WO2006047214A2
(en)
|
2004-10-21 |
2006-05-04 |
Igf Oncology, Llc |
Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer
|
US7446157B2
(en)
*
|
2004-12-07 |
2008-11-04 |
Key Medical Technologies, Inc. |
Nanohybrid polymers for ophthalmic applications
|
WO2006065724A2
(en)
*
|
2004-12-14 |
2006-06-22 |
Regents Of The University Of Minnesota |
Casein kinase 2 antisense therapy
|
KR20070110084A
(en)
|
2005-02-14 |
2007-11-15 |
오스트레일리언뉴클리어사이언스앤드테크놀로지오거나이제이션 |
Layered nanoparticles
|
US20060222692A1
(en)
*
|
2005-03-31 |
2006-10-05 |
Fairfield Clinical Trials Llc |
Method and compositions for transdermal administration of antimicrobial medications
|
EP1885854B1
(en)
*
|
2005-05-06 |
2012-10-17 |
Medtronic, Inc. |
Methods and sequences to suppress primate huntington gene expression
|
US7902352B2
(en)
*
|
2005-05-06 |
2011-03-08 |
Medtronic, Inc. |
Isolated nucleic acid duplex for reducing huntington gene expression
|
JP2008545808A
(en)
*
|
2005-05-23 |
2008-12-18 |
エラン・ファルマ・インターナショナル・リミテッド |
Nanoparticulate and controlled release compositions containing platelet aggregation inhibitors
|
US9133517B2
(en)
*
|
2005-06-28 |
2015-09-15 |
Medtronics, Inc. |
Methods and sequences to preferentially suppress expression of mutated huntingtin
|
US20080280843A1
(en)
*
|
2006-05-24 |
2008-11-13 |
Van Bilsen Paul |
Methods and kits for linking polymorphic sequences to expanded repeat mutations
|
EP1943016B1
(en)
|
2005-10-14 |
2012-08-15 |
Vive Crop Protection Inc. |
Composite nanoparticles, nanoparticles and methods for producing same
|
CN1962155A
(en)
*
|
2005-11-10 |
2007-05-16 |
鸿富锦精密工业(深圳)有限公司 |
CO2 laser welding apparatus
|
US7741396B2
(en)
*
|
2005-11-23 |
2010-06-22 |
General Electric Company |
Composites having tunable dielectric constants, methods of manufacture thereof, and articles comprising the same
|
EP1960001A2
(en)
*
|
2005-12-08 |
2008-08-27 |
Koninklijke Philips Electronics N.V. |
System and method for monitoring in vivo drug release using overhauser-enhanced nmr
|
EP2529761B1
(en)
|
2006-01-31 |
2017-06-14 |
Nanocopoeia, Inc. |
Nanoparticle coating of surfaces
|
WO2007089881A2
(en)
|
2006-01-31 |
2007-08-09 |
Regents Of The University Of Minnesota |
Electrospray coating of objects
|
US9108217B2
(en)
|
2006-01-31 |
2015-08-18 |
Nanocopoeia, Inc. |
Nanoparticle coating of surfaces
|
WO2007127799A2
(en)
*
|
2006-04-25 |
2007-11-08 |
Research Foundation Of The City University Of New York |
Polymer submicron particle preparation by surfactant- mediated precipitation
|
US9273356B2
(en)
|
2006-05-24 |
2016-03-01 |
Medtronic, Inc. |
Methods and kits for linking polymorphic sequences to expanded repeat mutations
|
WO2007149868A2
(en)
*
|
2006-06-20 |
2007-12-27 |
The Regents Of The University Of California |
Controlled release encapsulated anti-bacterial and anti-inflammatory nanoparticles
|
US20080039415A1
(en)
*
|
2006-08-11 |
2008-02-14 |
Gregory Robert Stewart |
Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
|
EP2051696A2
(en)
*
|
2006-08-18 |
2009-04-29 |
Morton Grove Pharmaceuticals, Inc. |
Stable liquid levetiracetam compositions and methods
|
US9375440B2
(en)
*
|
2006-11-03 |
2016-06-28 |
Medtronic, Inc. |
Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
|
US8324367B2
(en)
|
2006-11-03 |
2012-12-04 |
Medtronic, Inc. |
Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
|
US7819842B2
(en)
*
|
2006-11-21 |
2010-10-26 |
Medtronic, Inc. |
Chronically implantable guide tube for repeated intermittent delivery of materials or fluids to targeted tissue sites
|
US7988668B2
(en)
*
|
2006-11-21 |
2011-08-02 |
Medtronic, Inc. |
Microsyringe for pre-packaged delivery of pharmaceuticals
|
US9040816B2
(en)
|
2006-12-08 |
2015-05-26 |
Nanocopoeia, Inc. |
Methods and apparatus for forming photovoltaic cells using electrospray
|
US20080171906A1
(en)
*
|
2007-01-16 |
2008-07-17 |
Everaerts Frank J L |
Tissue performance via hydrolysis and cross-linking
|
EP1955695A1
(en)
*
|
2007-02-06 |
2008-08-13 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Nanocapsules of lipophilic complexes of nucleic acids
|
US20080193766A1
(en)
*
|
2007-02-13 |
2008-08-14 |
Northern Nanotechnologies |
Control of Transport to and from Nanoparticle Surfaces
|
EP2152241A4
(en)
*
|
2007-04-30 |
2012-11-14 |
Agency Science Tech & Res |
Method of delivering a protein into a cell
|
WO2008135855A2
(en)
|
2007-05-03 |
2008-11-13 |
Pfizer Products Inc. |
Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
|
WO2008135828A2
(en)
|
2007-05-03 |
2008-11-13 |
Pfizer Products Inc. |
Nanoparticles comprising a drug, ethylcellulose, and a bile salt
|
US9545384B2
(en)
|
2007-06-04 |
2017-01-17 |
Bend Research, Inc. |
Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
|
WO2008149192A2
(en)
|
2007-06-04 |
2008-12-11 |
Pfizer Products Inc. |
Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
|
WO2008157514A2
(en)
*
|
2007-06-14 |
2008-12-24 |
Genesegues, Inc. |
Metal ion-treated biocompatible polymers useful for nanoparticles
|
US9144546B2
(en)
|
2007-08-06 |
2015-09-29 |
Clsn Laboratories, Inc. |
Nucleic acid-lipopolymer compositions
|
US20090042825A1
(en)
*
|
2007-08-06 |
2009-02-12 |
Majed Matar |
Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer
|
US7973019B1
(en)
|
2007-10-03 |
2011-07-05 |
Alcon Research, Ltd. |
Transferrin/transferrin receptor-mediated siRNA delivery
|
TW200930405A
(en)
|
2007-11-15 |
2009-07-16 |
Alcon Res Ltd |
Low density lipoprotein receptor-mediated siRNA delivery
|
US8124594B2
(en)
*
|
2007-11-30 |
2012-02-28 |
Chemi Nutra, Llc |
Methods using phosphatidylserine, lysophosphatidylserine, and/or salts thereof to increase testosterone levels
|
WO2009073215A1
(en)
|
2007-12-06 |
2009-06-11 |
Bend Research, Inc. |
Pharmaceutical compositions comprising nanoparticles and a resuspending material
|
EP2240162A4
(en)
|
2007-12-06 |
2013-10-09 |
Bend Res Inc |
Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
|
WO2009085082A1
(en)
*
|
2007-12-28 |
2009-07-09 |
Dow Global Technologies Inc. |
Small scale functional materials
|
WO2009085083A1
(en)
*
|
2007-12-28 |
2009-07-09 |
Dow Global Technologies Inc. |
Phase compensation film comprising polymer nanoparticles imbibed with liquid crystal material
|
EP2252266A1
(en)
*
|
2008-02-11 |
2010-11-24 |
Yissum Research Development Company of the Hebrew University of Jerusalem |
Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
|
US8871276B2
(en)
|
2008-02-11 |
2014-10-28 |
Technion Research And Development Foundation Ltd. |
Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
|
US8865222B2
(en)
*
|
2008-02-11 |
2014-10-21 |
Technion Research And Development Foundation Ltd. |
Beta-casein assemblies for enrichment of food and beverages and methods of preparation thereof
|
WO2009101614A1
(en)
*
|
2008-02-11 |
2009-08-20 |
Technion Research & Development Foundation Ltd. |
Casein particles encapsulating therapeutically active agents and uses thereof
|
AP2966A
(en)
*
|
2008-02-18 |
2014-09-30 |
Csir |
Nanoparticle carriers for drug administration and process for producing same
|
CN101965195A
(en)
|
2008-03-05 |
2011-02-02 |
巴克斯特国际公司 |
Compositions and methods for drug delivery
|
IE20080211A1
(en)
|
2008-03-20 |
2009-11-25 |
Nat Univ Ireland |
Biodegradable nanoshells for delivery of therapeutic and/or imaging molecules
|
US20090269405A1
(en)
*
|
2008-04-08 |
2009-10-29 |
Appian Labs, Llc |
Enzyme mediated delivery system
|
WO2010006200A2
(en)
*
|
2008-07-09 |
2010-01-14 |
Board Of Regents, The University Of Texas System |
Triggered release of drugs from polymer particles
|
US8685458B2
(en)
|
2009-03-05 |
2014-04-01 |
Bend Research, Inc. |
Pharmaceutical compositions of dextran polymer derivatives
|
US10952965B2
(en)
*
|
2009-05-15 |
2021-03-23 |
Baxter International Inc. |
Compositions and methods for drug delivery
|
EA022699B1
(en)
|
2009-05-27 |
2016-02-29 |
Селекта Байосайенсиз, Инк. |
Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
|
WO2011017382A2
(en)
*
|
2009-08-03 |
2011-02-10 |
The Regents Of The University Of California |
Nanofibers and morphology shifting micelles
|
US8470304B2
(en)
|
2009-08-04 |
2013-06-25 |
Avidas Pharmaceuticals Llc |
Therapeutic vitamin D sun-protecting formulations and methods for their use
|
EP3311833A3
(en)
|
2009-08-26 |
2018-07-25 |
Selecta Biosciences, Inc. |
Compositions that induce t cell help
|
US9650244B2
(en)
|
2010-08-25 |
2017-05-16 |
Genesegues, Inc. |
Topical vaccination via DNA microparticles
|
US20120076735A1
(en)
*
|
2010-03-24 |
2012-03-29 |
Genesegues, Inc. |
Nanoparticles for Extravascular Administration
|
EA023397B1
(en)
|
2010-05-26 |
2016-05-31 |
Селекта Байосайенсиз, Инк. |
Synthetic nanocarrier combination vaccines
|
US8815294B2
(en)
|
2010-09-03 |
2014-08-26 |
Bend Research, Inc. |
Pharmaceutical compositions of dextran polymer derivatives and a carrier material
|
US8709487B1
(en)
|
2011-04-25 |
2014-04-29 |
The United States Of America As Represented By The Secretary Of The Army |
Nanoparticle entrapment of materials
|
WO2012149259A1
(en)
|
2011-04-29 |
2012-11-01 |
Selecta Biosciences, Inc. |
Tolerogenic synthetic nanocarriers to reduce antibody responses
|
US9060938B2
(en)
|
2011-05-10 |
2015-06-23 |
Bend Research, Inc. |
Pharmaceutical compositions of active agents and cationic dextran polymer derivatives
|
WO2012161677A1
(en)
|
2011-05-20 |
2012-11-29 |
Alcon Research, Ltd. |
TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
|
AU2012290306B2
(en)
|
2011-07-29 |
2017-08-17 |
Selecta Biosciences, Inc. |
Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses
|
US8932572B2
(en)
*
|
2011-08-26 |
2015-01-13 |
Arrowhead Madison Inc. |
Poly(vinyl ester) polymers for in vivo nucleic acid delivery
|
US9474715B2
(en)
*
|
2011-11-30 |
2016-10-25 |
Andreas Voigt |
Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition
|
EP3766516A1
(en)
|
2013-03-14 |
2021-01-20 |
President and Fellows of Harvard College |
Nanoparticle-based compositions
|
EA201592103A3
(en)
|
2013-05-03 |
2016-08-31 |
Селекта Байосайенсиз, Инк. |
METHODS AND COMPOSITIONS FOR STRENGTHENING CD4 + REGULATORY T-CELLS
|
CN112933218A
(en)
|
2013-06-04 |
2021-06-11 |
西莱克塔生物科技公司 |
Repeated administration of non-immunosuppressive antigen-specific immunotherapeutics
|
CN103550155A
(en)
*
|
2013-11-08 |
2014-02-05 |
江南大学 |
Method of restraining production of lysophosphatide in lecithin/non-ionic surfactant mixed micelles
|
CA2936675C
(en)
|
2014-01-12 |
2023-06-27 |
Igf Oncology, Llc |
Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
|
EA201692512A1
(en)
|
2014-06-25 |
2017-07-31 |
Селекта Байосайенсиз, Инк. |
METHODS AND COMPOSITIONS FOR THE TREATMENT BY SYNTHETIC NANOSEMS AND INHIBITORS OF THE IMMUNE CONTROL POINT
|
SG10201902499VA
(en)
|
2014-09-03 |
2019-04-29 |
Genesegues Inc |
Therapeutic nanoparticles and related compositions, methods and systems
|
CN106714826A
(en)
|
2014-09-07 |
2017-05-24 |
西莱克塔生物科技公司 |
Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
|
SI3215133T1
(en)
|
2014-11-05 |
2021-07-30 |
Selecta Biosciences, Inc. |
Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog
|
KR101663775B1
(en)
*
|
2014-11-13 |
2016-10-07 |
주식회사 엘지생활건강 |
Composition for stabilizing polyphenolic effective ingredient
|
AR106018A1
(en)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
|
EP3340982B1
(en)
|
2015-08-26 |
2021-12-15 |
Achillion Pharmaceuticals, Inc. |
Compounds for treatment of immune and inflammatory disorders
|
EP3426285B1
(en)
|
2016-03-11 |
2024-05-29 |
Cartesian Therapeutics, Inc. |
Formulations and doses of pegylated uricase
|
WO2018005552A1
(en)
|
2016-06-27 |
2018-01-04 |
Achillion Pharmaceuticals, Inc. |
Quinazoline and indole compounds to treat medical disorders
|
US20180085319A1
(en)
|
2016-09-27 |
2018-03-29 |
Takashi Kei Kishimoto |
Methods and compositions for treating cancer
|
WO2018094227A1
(en)
|
2016-11-17 |
2018-05-24 |
The University Of North Carolina At Chapel Hill |
Alkyl pyrrolopyrimidine analogs and methods of making and using same
|
KR20190104194A
(en)
|
2017-01-07 |
2019-09-06 |
셀렉타 바이오사이언시즈, 인크. |
Patterned Administration of Immunosuppressants Coupled to Synthetic Nanocarriers
|
CN110612122A
(en)
|
2017-03-11 |
2019-12-24 |
西莱克塔生物科技公司 |
Methods and compositions related to combination therapy with anti-inflammatory agents and synthetic nanocarriers comprising immunosuppressants
|
CN117442747A
(en)
|
2017-05-21 |
2024-01-26 |
Igf肿瘤公司 |
Insulin-like growth factor-chemotherapeutic conjugates for the treatment of myelodysplastic syndromes
|
MX2020003838A
(en)
|
2017-10-13 |
2020-08-06 |
Selecta Biosciences Inc |
Methods and compositions for attenuating anti-viral transfer vector igm responses.
|
US20190151470A1
(en)
*
|
2018-01-21 |
2019-05-23 |
RoverMed BioSciences, LLC |
Nanoparticles comprising protein-polynucleotide complexes and for delivering protein based complexes
|
CN108414393A
(en)
*
|
2018-06-13 |
2018-08-17 |
安徽中医药大学 |
A method of measuring entrapment efficiency of liposome
|
US20200038462A1
(en)
|
2018-07-16 |
2020-02-06 |
Selecta Biosciences, Inc. |
Methods and compositions of otc constructs and vectors
|
CA3106640A1
(en)
|
2018-07-16 |
2020-01-23 |
Selecta Biosciences, Inc. |
Methods and compositions of mma constructs and vectors
|
JP2021535112A
(en)
|
2018-08-20 |
2021-12-16 |
アキリオン ファーマシューティカルズ,インコーポレーテッド |
Pharmaceutical compounds for the treatment of medical disorders of complement D factor
|
EP3866773A4
(en)
|
2018-10-16 |
2022-10-26 |
Georgia State University Research Foundation, Inc. |
Carbon monoxide prodrugs for the treatment of medical disorders
|
MX2021013163A
(en)
|
2019-04-28 |
2022-02-21 |
Selecta Biosciences Inc |
Methods for treatment of subjects with preexisting immunity to viral transfer vectors.
|
MX2021014566A
(en)
|
2019-05-28 |
2022-03-22 |
Selecta Biosciences Inc |
Methods and compositions for attenuated anti-viral transfer vector immune response.
|
CN114207440A
(en)
|
2019-06-04 |
2022-03-18 |
西莱克塔生物科技公司 |
PEGylated uricase formulations and dosages
|
AU2020370129A1
(en)
|
2019-10-21 |
2022-05-12 |
Selecta Biosciences, Inc. |
Methods and compositions for treating liver diseases and disorders
|
WO2021092354A1
(en)
|
2019-11-08 |
2021-05-14 |
Selecta Biosciences, Inc. |
Formulations and doses of pegylated uricase
|
WO2021174013A1
(en)
|
2020-02-26 |
2021-09-02 |
Selecta Biosciences, Inc. |
Methods and compositions using synthetic nanocarriers comprising immunosuppressant
|
MX2022011248A
(en)
|
2020-03-11 |
2022-12-15 |
Selecta Biosciences Inc |
Methods and compositions related to synthetic nanocarriers.
|
EP4135693A1
(en)
|
2020-04-14 |
2023-02-22 |
Selecta Biosciences, Inc. |
Methods and compositions for inducing autophagy
|
WO2022150335A1
(en)
|
2021-01-05 |
2022-07-14 |
Selecta Biosciences, Inc. |
Viral vector dosing protocols
|
US20220323607A1
(en)
|
2021-04-09 |
2022-10-13 |
Selecta Biosciences, Inc. |
Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
|
WO2022261149A2
(en)
|
2021-06-09 |
2022-12-15 |
Scribe Therapeutics Inc. |
Particle delivery systems
|
WO2022261148A1
(en)
*
|
2021-06-09 |
2022-12-15 |
Scribe Therapeutics Inc. |
Compositions of glycoprotein particles
|
CA3235269A1
(en)
|
2021-10-12 |
2023-04-20 |
Cartesian Therapeutics, Inc. |
Viral vector dosing protocols
|
WO2023064367A1
(en)
|
2021-10-12 |
2023-04-20 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating anti-viral transfer vector igm responses
|
CA3237037A1
(en)
|
2021-11-14 |
2023-05-19 |
Cartesian Therapeutics, Inc. |
Multiple dosing with viral vectors
|
WO2023133319A1
(en)
|
2022-01-10 |
2023-07-13 |
Selecta Biosciences, Inc. |
High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
|
WO2023172628A1
(en)
|
2022-03-09 |
2023-09-14 |
Selecta Biosciences, Inc. |
Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
|
WO2023172624A1
(en)
|
2022-03-09 |
2023-09-14 |
Selecta Biosciences, Inc. |
Immunosuppressants in combination with anti-igm agents and related dosing
|
US20230372535A1
(en)
|
2022-03-25 |
2023-11-23 |
Selecta Biosciences, Inc. |
Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
|
US20230381277A1
(en)
|
2022-04-08 |
2023-11-30 |
Selecta Biosciences, Inc. |
High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
|
WO2024107889A1
(en)
|
2022-11-15 |
2024-05-23 |
Selecta Biosciences, Inc. |
Compositions and methods for treating primary biliary cholangitis
|